Antiestrogens affect both pathways of killer cell-mediated oncolysis

Anticancer Research

Volumn 20, Issue 3 A, 2000, Pages 1849-1853

  Haeryfar, Seyed Mohammad Mansour ^a   Nagy, Eva ^a   Baral, Edward ^b   Krepart, Garry ^b   Lotocki, Robert ^b   Berczi, Istvan ^a,c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c NONE   (Canada)

Author keywords

Antiestrogen; Killer cell; Oncolysis; Pathways

Indexed keywords

ANTIESTROGEN; CALCIUM CHELATING AGENT; CALCIUM ION; CHROMIUM 51; CIS TAMOXIFEN CITRATE; EGTAZIC ACID; FAS ANTIGEN; FAS LIGAND; MAGNESIUM CHLORIDE; MONOCLONAL ANTIBODY; PERFORIN; TAMOXIFEN; TOREMIFENE;

ARTICLE; CALCIUM CELL LEVEL; CELL STRAIN K 562; CONTROLLED STUDY; CYTOLYSIS; ERYTHROLEUKEMIA CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; KILLER CELL; OVARY CARCINOMA; PRIORITY JOURNAL; TARGET CELL;

ANTIGENS, CD95; ENDOPEPTIDASES; ESTROGEN RECEPTOR MODULATORS; FAS LIGAND PROTEIN; FEMALE; HUMANS; K562 CELLS; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; MEMBRANE GLYCOPROTEINS; OVARIAN NEOPLASMS; PORE FORMING CYTOTOXIC PROTEINS; SERINE ENDOPEPTIDASES; T-LYMPHOCYTES, CYTOTOXIC; TAMOXIFEN; TOREMIFENE;

EID: 0033863185     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Baral E, Nagy E, Kangas L, Berczi I: Antiestrogens enhance the therapeutic effect of lymphokine activated killer cells on the P815 murine mastocytoma. Int J Cancer 67: 580 - 585, 1996.
2. Baral E, Nagy E, Berczi I: The effect of tamoxifen on the immune response. In: Tamoxifen. Beyond the antiestrogen (Kellen JA, ed). Boston, Birkhauser, 1996, pp 137 - 178.
3. Mandeville R, Ghali SS, Chausseau JP: In vitro stimulation of human NK activity by an estrogen antagonist (tamoxifen). Eur J Cancer Clin Oncol 20: 983 - 985, 1984.
4. Baral E, Nagy E, Berczi I: Target cells are sensitized for cytotoxic T lymphocyte - mediated destruction by estradiol and tamoxifen. Int J Cancer 57: 1 - 5, 1994.
5. Baral E, Nagy E, Berczi I: Modulation of natural killer cell mediated cytoloxicity by tamoxifen and estradiol. Cancer 75: 591 - 599, 1995.
6. Baral E, Nagy E, Berczi I: Modulation of lymphokine - activated killer cell - mediated cytotoxicity by estradiol and tamoxifen. Int J Cancer 66: 214-218, 1996.
7. Baral E, Nagy E, Kangas L, Berczi I: Immunotherapy of the SL2-5 murine lymphoma with natural killer cells and tamoxifen or toremifene. Anticancer Res 17: 77 - 84, 1997.
8. Nagy E, Baral E, Kangas L, Berczi I: Antiestrogens potentiate the immunotherapy of P815 murine mastocytoma by cytotoxic T lymphocytes. Anticancer Res 17: 1083 - 1088, 1997.
9. Uslu R, Borsellino N, Frost P, Garban H, Ng CP, Mizutani Y, Belldegrun A, Bonavida B: Chemosensitization of human prostate carcinoma cell lines to anti-Fas-mediated cytotoxicity and apoptosis. Clin Cancer Res 3: 963 - 972, 1997.
10. Ioannides CG, Piatsoucas CD, Rashed S, Wharton TJ, Edwards CL, Freedman RS: Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. Cancer Res 51: 4257 - 4265, 1991.
11. Lozzio CB, Lozzio BB: Human chronic myelogenous leukemia cell - line with positive Philadelphia chromosome. Blood 45: 321 - 334, 1975.
12. Taniguchi N, Miyawaki T, Moriya N. Nagaoki T, Kato E: Mitogenic responsiveness and monocyte - lymphocyte interaction of early and late rosette - forming cell populations of human peripheral blood lymphocytes. J Immunol 118: 193 - 197, 1977.
13. Jordan CB: Metabolites of tamoxifen in animals and men. Identification, pharmacology and significance. Breast Cancer Res Treat 2: 123-126, 1982.
14. 51Cr-labelled allogeneic target cells in vitro: Inhibition by isoantibody and by drugs. Immunology 14: 181 - 196, 1968.
15. Roger R. Issaad C, Pallardy M, Leglise MC, Turhan AG, Bertoglio J, Breard J: BCR - ABL does not prevent apoptotic death induced by human natural killer or lymphokine - activated killer cells. Blood 87: 1113 - 1122, 1996.
16. Munker R, Marini F, Jiong S, Savary C, Owen - Schaub L, Andreeff M: Expression of CD95 (Fas) by gene transfer does not sensitize K562 to Fas-killing. Hematol Cell Ther 39: 75 - 78, 1997.
17. Williams BA, Makrigiannis AP, Blay J, Hoskin DW: Treatment of the P815 murine mastocytoma with cisplatin or etoposide up - regulates cell - surface Fas (CD95) expression and increases sensitivity to anti-Fas antibody - mediated cytotoxicity and to lysis by anti - CD3 -activated killer - T cells, Int J Cancer 73: 416 - 423, 1997.
18. Topalian SL, Muul LM, Solomon D, Rosenberg SA: Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods 102: 127-141, 1987.
19. Nagata S, Suda T: Fas and Fas ligand: lpr and gld mutations. Immunology Today 16: 39 - 42, 1995.
20. Uslu R, Jewett A, Bonavida B: Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-Fas antibody - mediated cytotoxicity and apoptosis. Gynecol Oncol 62: 282 - 291, 1996.
21. Frost P, Ng C, Belldegrun A, Bonavida B: Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK) - mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity. Cell Immunol 180: 70 - 83, 1997.
22. Owen - Schaub LB, Radinsky R, Kruzel E, Berry K, Yonehara S: Anti-Fas on nonhematopoietic tumors: levels of Fas/Apo-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res 54: 1580 -1586. 1994.
23. Brandenberger AW, Tee MK, Jaffe RB: Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down -regulation of ER-beta in neoplastic tissues. J Clin Endocrinol Metab 83: 1025 - 1028, 1998.
24. Baral E, Nagy E, Krepart GV, Lotocki RJ, Unruh HW, Berczi I: Antiestrogens sensitize human ovarian and lung carcinomas for lysis by autologous killer cells. Anticancer Res (in press).
25. Hoskin DW, Williams B, Fitzpatrick L, Makrigiannis AP: Cell biology and possible therapeutic applications of anti-CD3-activated killer-T cells (review). Int J Molecular Med 1: 893 - 902, 1998.
26. Berke G: The CTL's kiss of death. Cell 81: 9 - 12, 1995.
27. El-Khatib M, Stanger Z, Dogan H, Cui H, Ju S: The molecular mechanism of FasL - mediated cytotoxicity by CD4+ Th 1 clones. Cell Immunol 163: 237 - 244, 1995.
28. Montel AH, Bochan MR, Hobbs JA, Lynch DH, Brahmi Z: Fas involvement in cytotoxicity mediated by human NK cells. Cell Immunol 166: 236 - 246, 1995.
29. Vujanovic NL, Nagashima S, Herberman RB, Whiteside TL: Nonsecretory apoptotic killing by human NK cells. J Immunol 157: 1117 - 1126, 1996.
30. Teodorczyk - Injeyan J, Cambrzynska - Nowak M, Lalani S, Kellen JA: Modulation of biological responses of normal human mononuclear cells by antiestrogens. Anticancer Res 13: 279 - 283, 1993.
31. Gardiner CM, Reen DJ: Differential cytokine regulation of natural killer cell - mediated necrotic and apoptotic cytotoxicity. Immunology 93: 511-517, 1998.
32. Wargnier A, Lafaurie C, Legros - Maida S, Bourge JF, Sigaux F, Sasportes M, Paul P: Down - regulation of human granzyme B expression by glucocorticoids. Dexamethasone inhibits binding to the Ikaros and AP-1 regulatory elements of the granzyme B promoter. J Biol Chem 273: 35326 - 35331, 1998.